Discover Community Create You

Loading publication...

Noodle always counts identifier-free feature events for service operation. With your permission, Google Analytics can also estimate audience and engagement. Search text, publication identifiers, cookies, IP addresses and browser fingerprints are never included in Noodle's first-party event counters.

Privacy details

Article

Association analysis between the A118G polymorphism in the OPRM1 gene and treatment response to venlafaxine XR in generalized anxiety disorder.

Human psychopharmacology - 1 May 2013

Cooper Alissa J, Rickels Karl, Lohoff Falk W

Abstract excerpt

Patients diagnosed with generalized anxiety disorder (GAD) exhibit differential responses to standard antidepressant pharmacotherapy. Mounting evidence demonstrates that genetic differences may be implicated in treatment response in disorders like GAD. In this study, we examined whether the OPRM1 gene, which has been implicated in antidepressant treatment response in major depressive disorder, also has an effect...

Read the complete abstract on PubMed

Topics

Share this publication in a Topic to start or enrich a Post.

Share to Anxiety Disorders
Share to Cyclohexanols

Methodology Data sources Editorial policy Privacy About Contact Helena Bioinformatics

Share to Delayed-Action Preparations

Share to Double-Blind Method

Share to Receptors, Opioid, mu

Share to Secondary Prevention

Share to Selective Serotonin Reuptake Inhibitors

Share to Venlafaxine Hydrochloride

Source

Identifiers

PMID: 23658070
DOI: 10.1002/hup.2317

Genes

OPRM1

Provenance

PubMed metadata and Literature Corpus relationships. Corpus snapshot updated 7 Sept 2026. Manifest publication-graph-cohort-2026-09-07.1.

Source receipt: pubmed, retrieved 7 Sept 2026.

Related research

Semantic proximity does not establish scientific evidence.

Research trail→

Click a neighbor to travelStep 1 · 12 closest

Association analysis between the A118G polymorphism in the OPRM1 gene and treatment response to venlafaxine XR in generalized anxiety disorder.PMID 23658070Read ↗

Variation in the catechol-O-methyltransferase (COMT) gene and treatment response to venlafaxine XR in generalized anxiety disorder.Semantic proximity Read ↗

Association analysis between the Val66Met polymorphism in the brain-derived neurotrophic factor (BDNF) gene and treatment response to venlafaxine XR in generalized anxiety disorder.Semantic proximity Read ↗

Serotonin receptor 2A (HTR2A) gene polymorphism predicts treatment response to venlafaxine XR in generalized anxiety disorder.Semantic proximity Read ↗

The OPRM1 A118G Polymorphism Revisited: Recent Developments and Implications for Personalized Treatment.Semantic proximity Read ↗

Genome-wide association study of treatment response to venlafaxine XR in generalized anxiety disorder.Semantic proximity Read ↗

Interaction between polymorphisms in serotonin transporter (SLC6A4) and serotonin receptor 2A (HTR2A) genes predict treatment response to venlafaxine XR in generalized anxiety disorder.Semantic proximity Read ↗

Lack of influence of DAT1 and DRD2 gene variants on antidepressant response in generalized anxiety disorder.Semantic proximity Read ↗

Genetic polymorphisms in the PACAP and PAC1 receptor genes and treatment response to venlafaxine XR in generalized anxiety disorder.Semantic proximity Read ↗

Baseline serum oxytocin and OXTR rs53576 genotype are not predictive of escitalopram response in generalized anxiety disorder.Semantic proximity Read ↗

Meta-analysis of the relevance of the OPRM1 118A>G genetic variant for pain treatment.Semantic proximity Read ↗

Association of mu-opioid receptor variants and response to citalopram treatment in major depressive disorder.Semantic proximity Read ↗

Association of NPSR1 rs324981 polymorphism and treatment response to antidepressants in Chinese Han population with generalized anxiety disorder.Semantic proximity Read ↗

⌁Select a neighboring publication to make it the new centre.